Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of SDC1 monoclonal antibody, clone B-A38 (FITC)
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Mouse |
| Applications | Flow Cyt |
More info about SDC1 monoclonal antibody, clone B-A38 (FITC)
| Brand: | Abnova |
| Reference: | MAB5108 |
| Product name: | SDC1 monoclonal antibody, clone B-A38 (FITC) |
| Product description: | Mouse monoclonal antibody raised against native SDC1. |
| Clone: | B-A38 |
| Isotype: | IgG1 |
| Gene id: | 6382 |
| Gene name: | SDC1 |
| Gene alias: | CD138|SDC|SYND1|syndecan |
| Gene description: | syndecan 1 |
| Immunogen: | Native purified SDC1 from U266 human peripheral blood myeloma cell line. |
| Form: | Liquid |
| Recommend dilutions: | Flow Cytometry (20 ul in human blood cells 100 ul in whole blood or 106 cells in a suspension) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS (0.2% BSA, 0.09% sodium azide) |
| Storage instruction: | Store in the dark at 4°C. Do not freeze. Avoid prolonged exposure to light. Aliquot to avoid repeated freezing and thawing. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Conjugate tag: | FITC |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Antigen species / target species: | Human |
| Specificity: | This antibody recognizes CD138 (syndecan 1), a 65-70 KDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes. |
| Reactivity: | Human |
| Applications: | Flow Cyt |
| Shipping condition: | Blue Ice |
| Publications: | The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD. Blood. 2007 Sep 15;110(6):2041-8. Epub 2007 May 29. |